Eli Lilly and Company (NYSE: LLY) is repositioning its blockbuster drug Mounjaro, celebrated for its weight-loss and glucose-lowering effects, as a comprehensive therapeutic platform addressing cardiovascular and metabolic complications. The U.S. Food and Drug Administration (FDA) has recently authorized Mounjaro to reduce the risk of cardiovascular death, non-fatal heart attacks, or non-fatal strokes in adults with type 2 diabetes who also have established heart disease, thereby sharpening its competitive edge against Ozempic, the rival diabetes and weight-loss medication from Novo Nordisk.

Robust demand has already propelled Mounjaro's quarterly sales up 91% year-over-year to $9.94 billion. The newly approved cardiovascular indication not only broadens the eligible patient pool but also strengthens the case for insurance coverage, extending Lilly's addressable market from weight management and glycemic control into the far larger realm of cardiorenal metabolic diseases. It is crucial to distinguish that Mounjaro is the diabetes-branded version in the U.S., while Zepbound is the obesity-branded counterpart, both sharing the same active ingredient, tirzepatide. This approval applies to Mounjaro's cardiovascular indication and does not signify that Zepbound has been cleared for primary or secondary cardiovascular prevention.

Mounjaro and Zepbound share the identical pharmacological mechanism based on tirzepatide, but Mounjaro is primarily approved for type 2 diabetes and associated cardiovascular risk reduction (also serving weight loss for hyperglycemic patients), whereas Zepbound is indicated for long-term weight management in adults with obesity or overweight and related conditions.

Expanding Horizons: Mounjaro's New Cardiovascular Nod

Lilly has secured U.S. approval for Mounjaro to lower the risk of serious cardiovascular events, broadening its utility beyond blood sugar control and solidifying its position in the increasingly competitive GLP-1 drug class. The company announced on Friday that the FDA sanctioned Mounjaro for reducing cardiovascular risk in adults with type 2 diabetes and confirmed heart disease. Given that patients with diabetes and obesity face significantly higher odds of cardiovascular issues than the general population, a drug's capacity to prevent heart attacks, strokes, and cardiovascular death is a key metric of its value beyond glycemic efficacy. Novo Nordisk's competing diabetes injection, Ozempic, already holds an approved indication for cardiovascular disease. As of Thursday's market close, Lilly's shares were up roughly 9% year-to-date.

This significant FDA approval is grounded in a study involving over 13,000 participants, comparing Mounjaro to Trulicity, Lilly's older dedicated diabetes medication that has demonstrated heart-protective properties. In this trial, Mounjaro reduced the risk of heart attacks, strokes, and cardiovascular death, though it did not show superior efficacy compared to its predecessor. Nonetheless, the drug met its core research objective by proving it is at least nearly as effective as Trulicity in shielding the heart, and it also showed a 16% reduction in all-cause mortality among Mounjaro users.

For Lilly, this expanded indication adds yet another powerful tool to one of the pharmaceutical industry's most valuable product portfolios. Mounjaro and its obesity-focused partner Zepbound have become primary growth drivers for the Indianapolis-based pharma giant. Adding new indications helps Lilly reach more patients and provides a more compelling rationale for persuading insurers to cover these therapies. However, Lilly has not specifically conducted a trial for Zepbound on reducing cardiovascular disease risk. Instead, it is evaluating whether the obesity drug can lower all-cause mortality risk in a large, multi-year study, with results anticipated around 2027.

Beyond Weight Loss: The Science of Cardiometabolic Protection

The approval centers on Mounjaro's distinctive dual-receptor agonism involving glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This mechanism works by promoting insulin release in a glucose-dependent manner, suppressing inappropriate glucagon secretion, and modulating central appetite and satiety pathways while slowing gastric emptying and improving fat tissue and liver metabolism. Collectively, these actions lower blood glucose, body weight, visceral fat, blood pressure, and triglycerides while reducing insulin resistance and systemic inflammation. Consequently, the cardiovascular benefit is not just an incidental byproduct of weight loss but the outcome of synchronized improvements across multiple metabolic risk pathways, although whether there is a direct myocardial or vascular protective effect independent of weight loss still requires further mechanistic investigation.

Navigating the Future: Trials, Timing, and a $100 Billion Opportunity

Lilly's Mounjaro and Zepbound are well-positioned for continued label expansion, given that obesity, diabetes, obstructive sleep apnea, heart failure with preserved ejection fraction (HFpEF), chronic kidney disease, and metabolic dysfunction-associated steatotic liver disease all share pathophysiological underpinnings such as visceral adiposity, insulin resistance, chronic inflammation, and organ lipotoxicity. In trials of tirzepatide for obesity combined with HFpEF, the drug demonstrated a 38% reduction in heart failure outcomes and a 56% lower risk of hospitalization. Yet, each new indication must be validated through independent randomized trials demonstrating hard endpoint benefits, rather than extrapolating from weight loss alone. As Lilly hasn't initiated a dedicated Zepbound cardiovascular outcome trial, the extended study on all-cause mortality—expected to conclude by 2027—will be pivotal. Ultimately, the trajectory of label expansion and valuation will hinge on whether organ protection can clear the triple hurdles of statistical significance, regulatory approval, and insurance reimbursement.

Projections for the global pure-play obesity drug market around 2030 generally range from $95 billion to $105 billion, but when including diabetes, cardiovascular, and other metabolic indications, the broader market could approach $200 billion. Goldman Sachs forecasts the global anti-obesity drug market at roughly $95 billion by 2030, while Morgan Stanley's base case stands at $105 billion with a bull case reaching $144 billion. Starting from approximately $6 billion in 2023 sales, Morgan Stanley's base scenario implies a compound annual growth rate of about 50.5% from 2023 to 2030. JPMorgan, using a wider measurement scope, projects the global incretin market, encompassing both diabetes and obesity indications, to hit $200 billion by 2030.